Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.18 USD | -4.83% | -9.80% | 0.00% |
Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15M | Capitalization | 374M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 99.6M | Net cash position 2025 * | 53.37M | EV / Sales 2025 * | 21.4 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.81% |
1 day | -3.56% | ||
1 week | -6.82% | ||
Current month | -4.49% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 14.18 | -4.83% | 87 856 |
24-05-02 | 14.9 | -3.56% | 92,571 |
24-05-01 | 15.45 | -0.96% | 43,388 |
24-04-30 | 15.6 | -2.50% | 88,111 |
24-04-29 | 16 | +1.78% | 33,431 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 374M | |
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+45.32% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |
- Stock Market
- Equities
- CTNM Stock